News|Articles|October 3, 2026

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.

The third day of the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, delivered new long-term efficacy data, pregnancy safety findings, and expert perspectives across psoriasis, cutaneous lupus erythematosus, and atopic dermatitis.

Related to this article

October 2nd, 2026

Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.

October 1st, 2026

Check out highlights from news published on Day 2 of the EADV Congress 2026, spanning vitiligo, HS, atopic dermatitis, and more.

October 1st, 2026

Facial and total body repigmentation with upadacitinib kept rising through Week 76 in Viti-Up, with higher responses when NB-UVB was added.

October 1st, 2026

Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.

October 1st, 2026

The first controlled study of GLP-1 receptor agonists and nail health found nail detachment in 39% of users versus 9% of controls at EADV 2026.

September 30th, 2026

Check out highlights from news published on Day 1 of the EADV Congress 2026, spanning CSU, atopic dermatitis, HS, and more.

September 30th, 2026

Tulisokibart met its HiSCR50 primary endpoint at 16 weeks in the phase 2b MK-7240-012 trial assessing moderate to severe hidradenitis suppurativa.

September 30th, 2026

Intralesional BO-112 met its main endpoint in the phase 2b SPOTLIGHT-204 trial, with 61% of patients with resectable basal cell carcinoma responding.